Full-Time

Associate Director / Director

CMC Product Development

AbbVie

AbbVie

10,001+ employees

Global biopharmaceutical company developing medicines

Compensation Overview

$141.5k - $268.5k/yr

Waukegan, IL, USA

Hybrid

On-site three days per week (Tuesday–Thursday).

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)

Get referred to AbbVie

See people who can refer or advise you

Requirements
  • Bachelor’s Degree with at least 12 years of experience in a variety of relevant functions required; Master’s Degree with at least 10 years of relevant experience required; or PhD with at least 8 years of relevant experience required; 3-8 years of working experience required in the same/similar role or in related CMC function; For Associate Director: Bachelor’s Degree with at least 10 years of experience in a variety of relevant functions required; Master’s Degree with at least 8 years of relevant experience required; or PhD with at least 6 years of relevant experience required; 2-6 years of working experience required in the same/similar role or in related CMC function; Must possess excellent scientific writing and verbal communication skills; Must have a good working knowledge of regulatory requirements and familiarity with relevant scientific instrumentation and techniques; Deep knowledge of pharmaceutical drug development process; CMC interdisciplinary experience and expertise; Possess negotiating, influencing, leadership skills; Creative in implementing entrepreneurial thinking and making smart business decisions; Ensure high level of morale and collaboration in cross-functional teams to maximize team impact and output.
Responsibilities
  • Represents all CMC areas on the Asset Strategy Team (AST) serving as spokesperson for the CMC project team and ensures information flow among the AST and all line functions; Ensures high quality science, technology, deliverables, and certifies compliance with global regulatory and quality requirements; Participates in meetings with Regulatory Authorities, responds to regulatory queries, and participates in communications and meetings with regulatory agencies; Accountable for creating CMC development plan incl. timelines, risks and mitigations in collaboration with line functions and AST
  • Leads PPDST and/or CMC development teams for assigned projects: schedules meetings, develops agendas, issues highlights, identifies risks and develops mitigation plans with technical functions; Conducts periodic reviews to ensure that phase transition criteria are met in the most efficient and resource effective manner; Asset modalities may include new chemical entities (NCEs), new biological entities (NBEs), antibody-drug-conjugates (ADCs), toxins, and gene and cell therapies, incl. combination with complex delivery device constituents
  • Reviews contracts with Third Party Manufacturers and consultants; Develops budget needs in collaboration with AST, obtains resources from functional areas and stays within the approved funding; Drives legal and financial aspects of outsourcing, contracts, and statements of work (SOW); Demonstrates excellent interpersonal skills, ability to develop important relationships with external collaboration partners and key internal stakeholders; Demonstrates strong negotiating, influencing, and leadership skills
  • Leads teams and partner interactions for new due diligence in-licensing opportunities and successfully transitions leadership for programs where development is internalized
  • Manages several clinical development programs of higher complexity independently utilizing matrix management approach; Negotiates for additional resources when required, informs project timelines to ensure proper completion of required activities; Implements creative approaches to conserve resources, and achieve efficiency with respect to time, and budget; Provides feedback and input to functional managers and identifies growth needs for team members
  • Ensures strategic alignment with other key Development Sciences functions, esp. Preclinical Toxicology/Biological Sciences and QTAS/ADME to ensure key deliverables for asset advancement are met and risks and mitigation plans are in place; Integrates and implements pre-clinical development plans and updates as necessary in collaboration with the global development teams and respective line functions
  • Supports and implements corporate and division-level initiatives and strategies
  • Proposes, supports and implements and influences initiatives across CMC technical functions
  • Promotes scientific and entrepreneurial thinking, encourages creativity and manages quality and results with respect to science, time, budget and resources
  • Mentors PDD peers and/or other less experienced team members; Responsible for performance and career development of 0-3 direct reports
  • Ensures compliance with regulatory, health, safety and environmental requirements; Stay abreast of developments in global technical, regulatory and compliance arena and industry practice
  • Apprises management of plans and risks through regular communications, periodic reviews, in support of global filings, approvals and general agency feedback; Responsible for the quality and effectiveness of dossiers and communication with health authorities at global level

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AbbVie raised 2026 revenue guidance to $67.6 billion after Q2 2026.
  • FDA review of SKYRIZI Crohn's subcutaneous induction targets a late-2026 approval.
  • WCLC 2026 data showed ABBV-1480 90% response in squamous NSCLC.

What critics are saying

  • HUMIRA revenue fell 36.1% in Q2 2026 as biosimilars keep taking share.
  • The Apogee deal cuts 2026 EPS by $0.14 and adds debt financing.
  • Epcoritamab missed the July 23, 2026 DLBCL endpoint, threatening future B-cell franchise growth.

What makes AbbVie unique

  • SKYRIZI and RINVOQ drove $8.8 billion of Q2 2026 immunology revenue.
  • Botox Cosmetic and Juvederm generated $973 million in Q2 2026 aesthetics sales.
  • Apogee purchase adds late-stage IL-13 and TSLP programs for eczema and asthma.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Yahoo Finance
Aug 21st, 2026
AbbVie stock moves independently from market with 0.22 correlation driven by immunology drugs

AbbVie stock shows a correlation of just 0.22 to the S&P 500 over five years, meaning most of its movements stem from company-specific factors rather than broader market trends. The pharmaceutical firm's immunology segment generated nearly $8.8 billion of its $17 billion in second-quarter 2026 revenue, led by SKYRIZI at $5.5 billion and RINVOQ at over $2.5 billion. These treatments for chronic diseases have prices negotiated with payers, not consumers. AbbVie has delivered an annualised return of 21.5% with 23.5% volatility over five years, compared to the S&P 500's 12.9% return at 17.2% volatility. The company converts 28.3% of revenue into free cash flow, nearly double the S&P 500 median of 14.5%.

Grafa
Aug 21st, 2026
AbbVie reports 90% response in lung cancer study.

AbbVie reports 90% response in lung cancer study. * AbbVie reported a 90% objective response rate for ABBV-1480 plus platinum chemotherapy in squamous advanced NSCLC at the selected 10 mg/kg dose. * The same dose produced a 75.9% response rate in non-squamous disease and was selected as the recommended Phase 3 dose. * AbbVie will also present data for Temab-A and ABBV-706 across NSCLC and small cell lung cancer at the 2026 World Conference on Lung Cancer. AbbVie (NYSE:ABBV) reported Phase 1b lung cancer data showing objective response rates of 90% in squamous and 75.9% in non-squamous advanced NSCLC with ABBV-1480 plus platinum chemotherapy. At the 10 mg/kg dose, 27 of 30 patients with squamous disease and 22 of 29 with non-squamous disease achieved objective responses, according to the company. AbbVie said the findings support further evaluation of ABBV-1480 in advanced NSCLC and selected the 10 mg/kg regimen as the recommended Phase 3 dose. The company will present additional clinical results for telisotuzumab adizutecan, or Temab-A, in first-line non-squamous and EGFR-mutated NSCLC at the 2026 World Conference on Lung Cancer. AbbVie will also report ABBV-706 data in relapsed or refractory small cell lung cancer, including new safety analyses covering 240 patients. The company's conference presentations include real-world evidence evaluating SEZ6 as a potential therapeutic target in small cell lung cancer. The updates form part of AbbVie's clinical development program across non-small cell and small cell lung cancers, with several investigational therapies being evaluated across different treatment settings. Frequently asked questions. ABBV signals

Yahoo Finance
Aug 19th, 2026
AbbVie stock eyes breakout as Skyrizi dosing decision could unlock $24.5B revenue growth

AbbVie stock has returned 24.5% over the past three months, trading near its 52-week high. The pharmaceutical company's growth hinges on a pending regulatory decision for SKYRIZI, an immunology treatment that generates nearly a third of guided revenue. SKYRIZI sold $5.5 billion in Q2 2026, up 24% operationally. AbbVie guides the drug to $21.7 billion for 2026 against total company revenue of approximately $67.6 billion. The company has raised its 2026 guidance twice by $600 million combined. A subcutaneous induction option for Crohn's disease awaits regulatory approval this fall. Management expects the new dosing method to meaningfully accelerate SKYRIZI sales, though the commercial impact won't materialise until early 2027 due to contract timelines. Clinical trial results showed endoscopic response and remission rates 25 points above placebo.

BBC
Aug 19th, 2026
UK's Smith+Nephew CFO John Rogers to step down for external role.

UK's Smith+Nephew CFO John Rogers to step down for external role. August 19, 2026 The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing International News via Reuters: Smith+Nephew said on Wednesday its finance chief John Rogers would step down at the end of September to take up an external position in the United States, ending his roughly two-and-a-half-year tenure with the medical products company. Here are some more details: - The departure follows Smith+Nephew's decision weeks ago to cut its annual revenue growth forecast after second-quarter sales missed expectations due to weak U.S. knee and hip implant demand and pressure on skin substitute pricing. - Smith+Nephew said it had appointed Senior Vice President Finance and Group Controller Pierre Palassian as interim chief financial officer until a permanent replacement was appointed. - Palassian, who joined Smith+Nephew in 2017, previously held senior roles at AbbVie and Abbott Laboratories. - Rogers, who took up the CFO role in early 2024, had relocated to the United States in 2025 for operational efficiencies. - Shares in the FTSE 100 company have gained nearly 14% during Rogers' tenure as CFO. - Smith+Nephew said Rogers would receive no severance payment, and that his outstanding incentive and share awards would lapse on September 30 under leaver rules. Reporting by Neeshita Beura in Bengaluru; Editing by Subhranshu Sahu - Advertisement - August 19, 2026 - Advertisement -

Yahoo Finance
Aug 15th, 2026
AbbVie shows strong cash flow margin of 34.8% but faces tepid revenue growth

AbbVie, the biopharmaceutical company spun off from Abbott Laboratories in 2013, has risen 9.7% to $249.64 per share over the past six months. The company generates $64.39 billion in revenue over the past 12 months, benefiting from significant economies of scale in its operations. AbbVie's free cash flow margin averaged 34.8% over the last five years, amongst the best in the healthcare sector. This strong cash generation enables reinvestment and capital returns to investors. However, the company's five-year annualised revenue growth of 3.7% remains tepid compared to sector peers. Despite this weakness, AbbVie's shares trade at 16.3 times forward price-to-earnings ratio. The company develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.